Respiratory disease Archives

Morphogen IX pulmonary arterial hypertension

More News! 20 Dec 2018

Cambridge Company Raises €20M for Potential First in Lung Disease

Morphogen-IX, based in Cambridge, has raised €20.4M (£18.4M) to fund a new type of treatments for pulmonary arterial hypertension. The Series B financing will go towards the preclinical development of the company’s lead candidate, which has the potential to become the first to treat the condition rather than just addressing the symptoms. People with pulmonary […]

December 20, 2018 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 26 Nov 2018

Smart Asthma Inhaler Fails Phase III

It is bad news for asthma sufferers, as a UK biotech has abandoned the development of its smart inhaler after finding that it was no better than placebo in a Phase III trial. Over 52 weeks of treatment, the company Vectura tested whether the inhaler reduced the worsening of asthma symptoms, such as wheezing and […]

November 26, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 1 Aug 2018

London Biotech Raises €47M to Develop First Treatment Against RSV Virus

ReViral will dedicate the funds to run two clinical trials to test whether its antiviral can help patients at high risk from RSV infections. The respiratory syncytial virus (RSV) only causes mild cold symptoms in most people. But for small children and immunosuppressed patients, it can be deadly. “There are at present no approved therapies […]

August 1, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Apr 2018

British Biotech Raises £29M Round to Fight Lung Disease

Enterprise Therapeutics has raised a substantial Series B financing round to bring its treatments for respiratory diseases into clinical development. Enterprise Therapeutics, a British biotech, has raised £29M (€33M) in Series B from several investors including Forbion, one of the most active European life science VCs. In Enterprise, Forbion has found a replacement in its portfolio for the Dutch […]

April 12, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 5 Mar 2018

Danish Biotech Starts Phase III Atopic Dermatitis Trial With Failed Asthma Treatment

Danish biotech LEO Pharma started a Phase III trial in atopic dermatitis with an antibody that AstraZeneca dropped after failing two Phase III trials in asthma. LEO Pharma is taking over the development of the antibody tralokinumab from AstraZeneca to treat atopic dermatitis after the drug failed multiple Phase III studies for treating asthma. In […]

March 5, 2018 - 2 minutesmins - By Alexander Burik

Idorsia Actelion Spin Off Jean Paul Clozel CEO

News and Trends 1 Mar 2018

How is Actelion Spin-Off Idorsia Doing One Year Later?

Actelion’s spin-off Idorsia was blessed with a large pipeline and a healthy bank balance. How has the biotech’s first year of business gone? Just over a year ago, Actelion, the largest biotech in Europe at the time, was snapped up by Johnson & Johnson for a massive €27.9Bn. “This deal is unique: J&J gets its […]

March 1, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Feb 2018

Spring Cleaning: AstraZeneca Ditches Underperforming Asthma and Cancer Candidates

AstraZeneca has given up on the development of its PD-1 checkpoint inhibitor drug, which was the headline act when its subsidiary MedImmune acquired Amplimmune in 2013. There was no sentiment as pharma giant AstraZeneca cut a number of drugs from its pipeline after they did not perform as expected during clinical trials. The biggest name to get […]

February 6, 2018 - 3 minutesmins - By Alex Dale

News and Trends 5 Feb 2018

New Antiviral for RSV Lung Infections Shows Promise in Phase IIa

ReViral’s candidate RV521 showed its potential for the treatment of respiratory syncytial virus (RSV) infections by reducing viral load and mucus levels. London-based biotech ReViral discovers and develops antiviral drugs, focusing particularly on the treatment of diseases caused by the respiratory syncytial virus (RSV). The biotech’s candidate, RV521, has undergone a Phase IIa clinical trial during […]

February 5, 2018 - 3 minutesmins - By Alex Dale

News and Trends 11 Dec 2017

Could this British Biotech’s Drug Help to Bring Down COPD Hospitalizations?

Mereo BioPharma’s drug, BCT-197, more than halved the number of hospitalizations of chronic obstructive pulmonary disease patients during a Phase II trial. Mereo BioPharma develops therapies for patients with rare diseases. Today, it has announced that BCT-197, or acumapimod, improved lung function and reduced the number of hospitalizations for treatment in chronic obstructive pulmonary disease (COPD) patients. One of […]

December 11, 2017 - 3 minutesmins - By Alex Dale

News and Trends 14 Nov 2017

Dutch RNA Firm Announces a Public Offering when its Stock is at an All-Time Low

ProQR is aiming to raise funds for clinical trials on the Nasdaq despite the fact that its stock has been down for a while now. ProQR is a biotech based in Leiden that develops RNA therapies for genetic disorders, with its lead program focused on cystic fibrosis. In order to fund clinical trials, research and […]

November 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Oct 2017

No More Seasonal Flu Shots: British Biotech’s Universal Antiviral Raises £13M

VirionHealth kicks off the development of a broad spectrum antiviral for all influenza strains and other viruses like RSV with a £13M investment in Series A. VirionHealth is developing a new type of antiviral therapy with the potential to target multiple types of viruses at once. The treatment is based on natural antivirals called defective interfering viruses. They consist […]

October 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 12 Sep 2017

Shire’s Treatment for Chronic Lung Disease in Premature Infants Fast Tracked by FDA

The FDA has fast tracked Shire’s candidate for chronic lung disease in extremely premature infants from Phase 2 of clinical development. The FDA has fast tracked Shire’s candidate, SHP607, for the treatment of chronic lung disease based on preclinical data, the results of Phase I and II studies so far, and a lack of treatments […]

September 12, 2017 - 1 minutemin - By Alex Dale

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Respiratory disease

Cambridge Company Raises €20M for Potential First in Lung Disease

Smart Asthma Inhaler Fails Phase III

London Biotech Raises €47M to Develop First Treatment Against RSV Virus

British Biotech Raises £29M Round to Fight Lung Disease

Danish Biotech Starts Phase III Atopic Dermatitis Trial With Failed Asthma Treatment

How is Actelion Spin-Off Idorsia Doing One Year Later?

Spring Cleaning: AstraZeneca Ditches Underperforming Asthma and Cancer Candidates

New Antiviral for RSV Lung Infections Shows Promise in Phase IIa

Could this British Biotech’s Drug Help to Bring Down COPD Hospitalizations?

Dutch RNA Firm Announces a Public Offering when its Stock is at an All-Time Low

No More Seasonal Flu Shots: British Biotech’s Universal Antiviral Raises £13M

Shire’s Treatment for Chronic Lung Disease in Premature Infants Fast Tracked by FDA

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!